BTAI PE Ratio & Valuation, Is BTAI Overvalued

Historical Valuation

BioXcel Therapeutics Inc (BTAI) is now in the Fair zone, suggesting that its current forward PS ratio of 27.88 is considered Fairly compared with the five-year average of -2.41. The fair price of BioXcel Therapeutics Inc (BTAI) is between 0.16 to 2.27 according to relative valuation method.

Relative Value

Fair Zone

0.16-2.27

Current Price：1.61

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BioXcel Therapeutics Inc (BTAI) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BioXcel Therapeutics Inc (BTAI) has a current Price-to-Book (P/B) ratio of -0.38. Compared to its 3-year average P/B ratio of 3.48, the current P/B ratio is approximately -111.00% higher. Relative to its 5-year average P/B ratio of 3.56, the current P/B ratio is about -110.73% higher. BioXcel Therapeutics Inc (BTAI) has a Forward Free Cash Flow (FCF) yield of approximately -156.58%. Compared to its 3-year average FCF yield of -290.34%, the current FCF yield is approximately -46.07% lower. Relative to its 5-year average FCF yield of -177.02%, the current FCF yield is about -11.55% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BTAI competitors is 6.44, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI.O) exhibits a P/S ratio of 27.88, which is 332.85% above the industry average. Given its robust revenue growth of -54.21%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BTAI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BTAI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BTAI currently overvalued or undervalued?

What is BioXcel Therapeutics Inc (BTAI) fair value?

BTAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioXcel Therapeutics Inc (BTAI) is between 0.16 to 2.27 according to relative valuation method.

How does BTAI's valuation metrics compare to the industry average?

The average P/S ratio for BTAI's competitors is 6.44, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI) exhibits a P/S ratio of 27.88, which is 332.85% above the industry average. Given its robust revenue growth of -54.21%, this premium appears unsustainable.

What is the current P/B ratio for BioXcel Therapeutics Inc (BTAI) as of Mar 07 2026?

As of Mar 07 2026, BioXcel Therapeutics Inc (BTAI) has a P/B ratio of -0.38. This indicates that the market values BTAI at -0.38 times its book value.

What is the current FCF Yield for BioXcel Therapeutics Inc (BTAI) as of Mar 07 2026?

As of Mar 07 2026, BioXcel Therapeutics Inc (BTAI) has a FCF Yield of -156.58%. This means that for every dollar of BioXcel Therapeutics Inc's market capitalization, the company generates -156.58 cents in free cash flow.

What is the current Forward P/E ratio for BioXcel Therapeutics Inc (BTAI) as of Mar 07 2026?

As of Mar 07 2026, BioXcel Therapeutics Inc (BTAI) has a Forward P/E ratio of -0.41. This means the market is willing to pay $-0.41 for every dollar of BioXcel Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioXcel Therapeutics Inc (BTAI) as of Mar 07 2026?

As of Mar 07 2026, BioXcel Therapeutics Inc (BTAI) has a Forward P/S ratio of 27.88. This means the market is valuing BTAI at $27.88 for every dollar of expected revenue over the next 12 months.

BTAI Valuation